Following how ischemic stroke from a blocked medium-sized brain artery is treated
Observes how adults with stroke from medium vessel blockage are treated in practice.
Plain-language title generated from the registry record
Registry title: PROMISE Registry: PROspective Study on Management of Ischemic Stroke Secondary to mEvo Registry
Key facts
- Where
- Indianapolis, United StatesSee the site
Could this be for you?
Answer for yourself. This is not a decision: only the study team can say whether you can take part.
- Are you between 18 and 85 years old?
Source: NCT07746947, who can take part
Where in United States
- IU Health Neuroscience CenterIndianapolis, United StatesTaking people
Questions to ask the study team
- How often do I need to come in, and for how long each time?
- Are travel costs paid?
- Can I keep my own doctor?
- What happens if I want to stop?
Trial details
- Who runs it
- Indiana University
- Trial code
- NCT07746947
- Record updated
- 5 August 2026
- Original description
Investigators are conducting a real world, observational, prospective, multicenter study to better understand treatment for patients with MeVo and distal vessel occlusions in the U.S post publication of recent MeVO trials.Read full original descriptionShow less
PROMISE Registry: PROspective Study on Management of Ischemic Stroke Secondary to mEvo Registry
Investigators are conducting a real world, observational, prospective, multicenter study to better understand treatment for patients with MeVo and distal vessel occlusions in the U.S post publication of recent MeVO trials.
Exclusion: Intracranial tumors other than small meningioma that does not require surgery for one year post randomization; Life expectancy is less than one year prior to stroke onset14. Participation in another randomized clinical trial that could confound the evaluation of the study outcomes; Any intracranial hemorrhage on initial CT head non contrast; Known pregnancy (local protocol to determine if patient is pregnant at the time of stroke); Known severe allergy (more than a rash) to contrast media uncontrolled by medications; CT evidence of the following conditions:; Midline shift or herniation; Mass effect with effacement of the ventricles; Any other condition (in the opinion of the site investigator) that precludes an endovascular procedure or poses a significant hazard to the patient if an endovascular procedure was performed; Known hemorrhagic diathesis, coagulation factor deficiency, or on anticoagulant therapy with an International Normalized Ratio (INR) of >3.0 or Partial Thromboplastin Time (PTT) >3 times of normal; Baseline platelet count <80,000 per microliter (µl); Age >86; ASPECTS ≤ 5; mRS≥3; Acute bilateral strokes; Contraindication to antiplatelet (aspirin, clopidogrel, ticagrelor, cangrelor) or contrast agents.
Inclusion; Acute ischemic stroke clinically eligible for immediate EVT; Age ≥18 - 85 years of age; Time from onset (or last-seen-well) to 24 hours; Disabling stroke defined as follows:; Baseline National Institutes of Health Stroke Scale (NIHSS) score >5 B. Baseline NIHSS 3-5 with disabling deficit (e.g., hemianopia, aphasia, loss of hand function) as determined and agreed upon by two physicians in context of the patient's life; Confirmed treatable MeVO based on neurovascular non-invasive imaging (CTA or MRA), at one or more of the following locations: M2 or M3 segment, A2 or A3 segment, P1, P2 or P3 segment; Informed consent: Within the first 72 hours after inclusion in the study; ASPECTS ≥5; mRS≤2.